Vincent A. Miller
Thoracic Oncology Service
Division of Solid Tumor Oncology
Department of Medicine
Memorial Sloan-Kettering Cancer Center
USA
Name/email consistency: high
- Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. Miller, V.A., Riely, G.J., Zakowski, M.F., Li, A.R., Patel, J.D., Heelan, R.T., Kris, M.G., Sandler, A.B., Carbone, D.P., Tsao, A., Herbst, R.S., Heller, G., Ladanyi, M., Pao, W., Johnson, D.H. J. Clin. Oncol. (2008)
- EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer. Miller, V.A. Semin. Oncol. Nurs (2008)
- Optimizing therapy in previously treated non-small cell lung cancer. Miller, V.A. Semin. Oncol. (2006)
- Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities. Miller, V.A., Hirsch, F.R., Johnson, D.H. J. Clin. Oncol. (2005)
- Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. Miller, V.A., Kris, M.G., Shah, N., Patel, J., Azzoli, C., Gomez, J., Krug, L.M., Pao, W., Rizvi, N., Pizzo, B., Tyson, L., Venkatraman, E., Ben-Porat, L., Memoli, N., Zakowski, M., Rusch, V., Heelan, R.T. J. Clin. Oncol. (2004)
- Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. Miller, V.A., Johnson, D.H., Krug, L.M., Pizzo, B., Tyson, L., Perez, W., Krozely, P., Sandler, A., Carbone, D., Heelan, R.T., Kris, M.G., Smith, R., Ochs, J. J. Clin. Oncol. (2003)
- Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer. Miller, V.A., Krug, L.M., Ng, K.K., Pizzo, B., Perez, W., Heelan, R.T., Kris, M.G. J. Clin. Oncol. (2000)
- Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. Miller, V.A., Benedetti, F.M., Rigas, J.R., Verret, A.L., Pfister, D.G., Straus, D., Kris, M.G., Crisp, M., Heyman, R., Loewen, G.R., Truglia, J.A., Warrell, R.P. J. Clin. Oncol. (1997)
- Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer. Miller, V.A., Rigas, J.R., Tong, W.P., Reid, J.R., Pisters, K.M., Grant, S.C., Heelan, R.T., Kris, M.G. Cancer Chemother. Pharmacol. (1997)
- Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Miller, V.A., Ng, K.K., Grant, S.C., Kindler, H., Pizzo, B., Heelan, R.T., von Roemeling, R., Kris, M.G. Ann. Oncol. (1997)